• Vedanta Biosciences

  Participated · Series D · Jul 2021

  Vedanta's lead program, VE303, is an orally administered live biotherapeutic product comprising a defined consortium of eight bacterial strains, developed to prevent recurrent Clostridioides difficile infection. VE303 is produced from pure, clonal bacterial cell banks to yield a standardized powdered drug product and has received FDA Orphan Drug designation (2017) and Fast Track designation (2023). The registrational Phase 3 RESTORATiVE303 trial is randomized, double-blind and placebo-controlled with a 2:1 randomization and a primary endpoint of CDI recurrence rate at Week 8. RESTORATiVE303 is enrolling across more than 150 sites in about 20 countries, has passed a DMC interim analysis recommending continuation, and is expected to complete enrollment in H2 2026 with topline data in H1 2027. Vedanta is funding the trial through the recent $60M financing package and supplemental BARDA funding. The company intends the RESTORATiVE303 study to form the basis for a Biologics License Application to the U.S. FDA.

• Federation Bio

  Participated · Series A · Oct 2020

  Federation Bio develops microbial therapeutics by combining large numbers of microbial strains into highly diverse consortia, in some cases optimized with genetically engineered bacteria to enhance immune responses. The company’s lead program targets secondary hyperoxaluria, a condition affecting more than 200,000 Americans, with the goal of entering the clinic in 2022. Federation Bio will use the Series A proceeds to build out an in-house development process to enable Phase 1/2 manufacturing and to advance its lead program into the clinic. The company closed a $50M Series A financing to support these plans. Federation Bio was founded by Michael Fischbach, Ph.D., and Dylan Dodd, M.D., Ph.D.; both founders are professors at Stanford University. Leadership changes announced alongside the financing include Emily Drabant Conley, Ph.D., being named CEO, replacing founding CEO Racquel Bracken, and the additions of John Stuelpnagel, D.V.M., and Dr. Conley to the board.

• ENTEROME

  Participated · Series E · Jun 2020

  Enterome is a clinical-stage company developing first-in-class OncoMimics immunotherapies, led by lead candidate EO2463. EO2463 is an off-the-shelf immunotherapy combining four synthetic OncoMimics peptides that mimic B‑cell markers (CD20, CD22, CD37 and CD268/BAFF receptor) plus a helper peptide (UCP2) to target malignant B lymphocytes. The approach aims to provide broad target coverage to improve safety and maximize efficacy while reducing antigen-escape driven resistance. Enterome is expanding and finalizing its Phase 1/2 SIDNEY clinical trial and preparing EO2463 for a registrational program, including a planned pivotal Phase 3 for the “watch-and-wait” iNHL population. The company has held positive interactions with regulators (FDA Type C meeting and EMA Scientific Advice) that outline a clear path to marketing authorization in watch-and-wait iNHL. New and prior clinical data (including ASCO 2024 and upcoming ICML presentation) support EO2463’s activity as monotherapy and in combination and suggest biomarker-driven identification of likely responders. Enterome leverages its understanding of the gut microbiome–immune interaction to discover and develop small molecules, proteins and peptide therapeutics for cancer, autoimmune, inflammatory and metabolic diseases. Its pipeline includes cancer immunotherapies (EO2401, EO2463), EndoMimics biologics (EM101) for inflammatory diseases, and EB8018 (sibofimloc/TAK-018), an oral FimH blocker advancing in Crohn’s disease trials. EO2401 was expected to enter Phase 1/2 trials in glioblastoma and adrenal malignancies in mid-2020, while EO2463 is being prepared as a clinical candidate for B‑cell malignancies. EB8018 is partnered globally with Takeda, with Enterome retaining a significant profit share in the US. The company has operations in Paris and Boston and is led by CEO Pierre Belichard. Enterome recently closed a €46.3M financing and drew the first tranche from a previously agreed European Investment Bank loan facility to support clinical development. Enterome is a clinical-stage biotech pioneering microbiome-derived pharmaceuticals and diagnostics targeting inflammatory bowel diseases and cancer. Its lead programs are EB8018, an oral gut‑restricted FimH blocker for Crohn’s disease, and EO2315, an immuno‑oncology candidate derived from bacterial antigens. EB8018 completed a Phase 1 trial in 2017 showing safety and minimal blood absorption and is advancing to Phase 2; EO2315 has produced strong immune responses and tumor cell‑killing ex vivo and controlled tumor growth in vivo and is entering a Phase 1b study in glioblastoma. The company is also developing the next generation of its proprietary metagenomics drug discovery platform to expand therapeutic target discovery. Enterome has established partnerships with pharmaceutical companies (including Johnson & Johnson/Janssen, Takeda, Abbvie and Bristol‑Myers Squibb) and a 50/50 joint venture with Nestlé Health Science for microbiome diagnostics. The company was founded in 2012 in Paris. Enterome Bioscience SA, based in Paris and Boston, pioneers pharmaceuticals and diagnostics derived from the gut microbiome. Its lead therapeutic candidate is EB 8018, a novel small-molecule FimH antagonist licensed from Vertex that targets Adherent Invasive Escherichia coli (AIEC) proliferation. EB 8018 is being developed as a potential treatment for inflammatory bowel diseases and acts by preventing AIEC adhesion to the gut wall to help restore a dysbiotic microbiome. The company also develops microbiome-based diagnostics for IBD and other microbiome-related diseases and seeks partnerships with diagnostic and pharmaceutical companies. Enterome intends to advance therapeutic programs in immuno-oncology alongside its diagnostics and gut-focused therapies. The company will use the recent financing to support moving EB 8018 into first clinical studies in 2016. Enterome Bioscience develops disease management solutions and diagnostic products grounded in gut microbiome science. The company is building diagnostic tools to support patient stratification, personalized therapies and the clinical development of new drugs. Target indications include microbiome-related diseases such as inflammatory bowel diseases and metabolic diseases like diabetes and obesity. Enterome intends to use newly raised funds for R&D and business development activities. Founded in 2012 and led by CEO Pierre Belichard, the company is based in Paris, France. To date it has raised a total of €17.5m.

• MycoTechnology

  Participated · Series B · Oct 2017

  MycoTechnology harnesses the metabolic engine of mushrooms—mycelium—using natural fermentation to produce novel food ingredients. Its product portfolio includes ClearIQ, a kosher and halal all‑natural bitter blocker, and FermentIQ, a plant‑based meat analog ingredient made by fermenting pea and rice protein with shiitake mycelium. The company positions its ingredients as solutions for sugar reduction, food insecurity, sustainable protein and natural immune support, and aims to improve taste and functionality in plant‑based products. Founded in 2013 and based in Aurora, Colorado, MycoTechnology says its platform can add new-to-the-world ingredients from the fungal kingdom. The startup plans to use recent funding to further capitalize its fermentation technology platform and expand its geographical footprint, prioritizing launches in Europe, Asia and the Middle East. MycoTechnology emphasizes improving the palatability of alt‑protein to help drive broader consumer adoption. MycoTechnology develops a mushroom fermentation platform to create food-processing solutions and functional ingredients made from mycelium. The company is Colorado-based and was selected from more than 150 global applicants to win the Radicle Protein Challenge, receiving a US$1 million investment prize. It previously closed a US$39 million Series D backed by Greenleaf Foods, Tyson Ventures and Eighteen94 Capital. Management has stated plans to expand its line of ingredients and food-processing solutions made using mycelium. The company also alluded to an opportunity for an IPO in late 2022. As part of the prize, MycoTechnology will gain access to the agricultural network and expertise of Radicle and Syngenta to accelerate its technology. MycoTechnology develops mushroom-based functional ingredients, including ClearTaste (a bitterness masker) and PureTaste, a fermented pea-and-rice protein that is 77% protein. The company raised $39M in a Series D to help build and scale its functional ingredients platform. PureTaste is produced by fermenting pea and rice protein with shiitake mycelia and is positioned for use in meat alternatives, snack bars, dairy alternatives, and baked goods. ClearTaste is commonly used to mask the aftertaste of stevia, enabling sugar reduction, and is also used in CBD products, coffee, chocolate, and low-sodium formulations made with potassium chloride. MycoTechnology's CEO, Alan Hahn, has said the company has projects that may create opportunities to go public, with a previously announced IPO plan for late 2022. The article also situates the company within a growing mycoprotein market, noting industry expansion and other recent fundraising by fungi-based ingredient startups. MycoTechnology is a Denver, CO–based developer of a novel organic food processing platform that transforms agricultural material into functional ingredients. Its offering includes ClearTaste, which enables companies to reduce sugar by blocking bitterness, and PureTaste®, a sustainable, functional, plant-based protein. The company is led by CEO Alan Hahn, CSO Anthony Clark, COO Rick Becker, and CFO Jonathan Jachimiec. MycoTechnology closed a $30M Series C to accelerate expansion, speed R&D project execution, and grow the team to support current and future projects. The firm targets major challenges in the food and beverage industry by commercializing ingredient solutions derived from its platform. MycoTechnology develops functional food ingredients using mushroom fermentation, commercializing products for the food and beverage industry. Its first product, ClearTaste®, is a certified organic bitter blocker that helps companies reduce sugar in their products. The company is commercializing a Shiitake-fermented vegetable protein called PureTaste, which the article describes as highly digestible, non-GMO, vegan, low in calories/fats/carbohydrates and rich in vitamins and minerals not found in competing proteins. After ClearTaste commercialization, MycoTechnology is focusing on addressing challenges in the protein industry with PureTaste. The company intends to use new funds to continue to grow operations, and its commercial facility will initially be able to produce 4,000 metric tons of PureTaste per year. MycoTechnology was founded in 2013 by Alan Hahn, who serves as CEO.

No current team members are available.